Trademark: 85619481
Word
SOLCO HEALTHCARE U.S.
Status
Dead
Status Code
710
Status Date
Friday, September 11, 2020
Serial Number
85619481
Registration Number
4478651
Registration Date
Tuesday, February 4, 2014
Mark Type
4000
Filing Date
Tuesday, May 8, 2012
Published for Opposition
Tuesday, March 5, 2013
Cancellation Date
Friday, September 11, 2020

Trademark Owner History
Solco Healthcare US, LLC - Original Registrant

Classifications
5 Analgesic and muscle relaxant pharmaceutical preparations; antibacterial pharmaceuticals; antimicrobial preservatives for cosmetics and pharmaceuticals; pharmaceutical astringents; balms for pharmaceutical purposes; cream of tartar for pharmaceutical purposes; creosote for pharmaceutical purposes; dermatological pharmaceutical products; digestives for pharmaceutical purposes; drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; drug delivery agents in the form of tablets that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; drug delivery agents in the form of powders that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; ferments for pharmaceutical purposes; inhaled pharmaceutical preparations for the treatment of respiratory disease; injectable pharmaceuticals for treatment of anaphylactic reactions; intravenous fluids used for rehydration, nutrition and the delivery of pharmaceutical preparations; iodine for pharmaceutical purposes; liquorice for pharmaceutical purposes; menthol for pharmaceutical purposes; pharmaceutical antitussive-cold preparations; pharmaceutical anti-allergic preparations and substances; pharmaceutical for the treatment of erectile dysfunction; pharmaceutical preparations, namely, anticoagulants; pharmaceutical preparations, namely, appetite suppressants; pharmaceutical preparation for the treatment of gout; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical preparations, namely, a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents; pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; pharmaceutical preparations for treating allergic rhinitis and asthma; pharmaceutical preparations for use in urology; pharmaceutical preparations for the treatment of eye diseases and conditions; pharmaceutical preparations, namely, a topical preparation for the treatment of ocular disorders prescribed by ophthalmologists, eye surgeons, and optometrists; pharmaceutical preparations for the treatment of immune system related diseases and disorders; pharmaceutical preparations, namely, injectable contraceptives; pharmaceutical preparations for treating allergies; pharmaceutical preparations for treating hypertension; pharmaceutical products for treating respiratory disease and asthma; pharmaceutical products for the treatment of joint disease; plant extracts for medical, veterinary and pharmaceutical purposes; potassium preparations for pharmaceutical purposes; pharmaceutical preparations and substances for weight loss; vitamin and mineral supplements for use as ingredients in the food and pharmaceutical industry; drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; drug delivery agents in the form of coatings for facilitating the delivery of a wide range of pharmaceuticals; drug delivery agents in the form of tablets that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; biological preparations for the treatment of cancer and autoimmune deficiencies and disorders; pharmaceutical, veterinary and sanitary preparations, namely, conjugates of organic and inorganic chemicals with polypeptides, proteins, artificial polypeptides, artificial proteins produced by genetic engineering and for the treatment of viral and infectious diseases, immune system disorders, cancer, diabetes, cardiovascular diseases, central nervous system disorders and diseases; anti-diabetic pharmaceuticals; pharmaceutical preparations for treating diabetes; pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, for the treatment of bacteria-based diseases, and for the treatment of diabetes, and anti-infective preparations, antiviral preparations, antibiotics, antifungal preparations and vaccines; cardiovascular pharmaceuticals; pharmaceutical preparations for the treatment of heart rhythm disorders; pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; prescription and non-prescription medicines, namely, pills, tablets, capsules, caplets, liquid drops, sachets and pharmaceutical preparations for the treatment of cardiovascular disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the treatment of psychiatric diseases and disorders; pharmaceutical preparations for treating skin disorders; pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer
35 Providing business intelligence services in the fields of medical devices, pharmaceuticals and the life sciences; regulatory submission management, namely, assisting others in preparing and filing applications for new drugs with governmental regulatory bodies
44 Medical and pharmaceutical consultation
Color is not claimed as a feature of the mark.
"HEALTHCARE U.S."

Trademark Events
Sep 11, 2020
Cancelled Sec. 8 (6-Yr)
Feb 4, 2019
Courtesy Reminder - Sec. 8 (6-Yr) E-Mailed
Feb 4, 2014
Registered-Principal Register
Dec 31, 2013
Notice Of Acceptance Of Statement Of Use E-Mailed
Dec 28, 2013
Law Office Registration Review Completed
Dec 27, 2013
Assigned To Lie
Dec 23, 2013
Allowed Principal Register - Sou Accepted
Dec 23, 2013
Examiner's Amendment Entered
Dec 19, 2013
Notification Of Examiners Amendment E-Mailed
Dec 19, 2013
Examiners Amendment E-Mailed
Dec 19, 2013
Su-Examiner's Amendment Written
Nov 21, 2013
Notification Of Non-Final Action E-Mailed
Nov 21, 2013
Non-Final Action E-Mailed
Nov 21, 2013
Su - Non-Final Action - Written
Nov 10, 2013
Statement Of Use Processing Complete
Oct 30, 2013
Use Amendment Filed
Oct 30, 2013
Teas Statement Of Use Received
Aug 28, 2013
Applicant/Correspondence Changes (Non-Responsive) Entered
Aug 26, 2013
Case Assigned To Intent To Use Paralegal
Aug 5, 2013
Teas Withdrawal Of Attorney Received-Firm Retains
Apr 30, 2013
Noa E-Mailed - Sou Required From Applicant
Mar 5, 2013
Official Gazette Publication Confirmation E-Mailed
Mar 5, 2013
Published For Opposition
Feb 13, 2013
Notification Of Notice Of Publication E-Mailed
Jan 29, 2013
Law Office Publication Review Completed
Jan 25, 2013
Approved For Pub - Principal Register
Jan 24, 2013
Examiner's Amendment Entered
Jan 24, 2013
Notification Of Examiners Amendment E-Mailed
Jan 24, 2013
Examiners Amendment E-Mailed
Jan 24, 2013
Examiners Amendment -Written
Jan 5, 2013
Teas/Email Correspondence Entered
Jan 5, 2013
Correspondence Received In Law Office
Dec 27, 2012
Assigned To Lie
Dec 19, 2012
Teas Response To Office Action Received
Sep 5, 2012
Notification Of Non-Final Action E-Mailed
Sep 5, 2012
Non-Final Action E-Mailed
Sep 5, 2012
Non-Final Action Written
Aug 29, 2012
Assigned To Examiner
May 15, 2012
New Application Office Supplied Data Entered In Tram
May 11, 2012
New Application Entered In Tram

Trademark Alertz updated from USPTO on 2030-01-24